PharmAust Limited (ASX: PAA & PAAOA) is thrilled to announce the completion of enrollment for the Open-Label Extension (OLE) study, showing a remarkable survival benefit for monepantel (MPL) compared to untreated matched-controls from the PRO-ACT database for patients with Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS). The updated analysis by Berry Consultants demonstrated a 91% reduction in the risk of death with MPL treatment, further emphasizing the potential impact of our therapeutic approach.<br/><br/>In addition, the updated efficacy analysis revealed that MPL continues to slow the rate of disease progression in patients with MND/ALS. These positive outcomes pave the way for the upcoming pivotal adaptive Phase 2/3 STRIKE study scheduled to commence in H2 2024.<br/><br/>We are proud to have achieved this significant milestone and are excited about the potential of our innovative treatment in improving outcomes for patients with neurodegenerative diseases. For more information or to inquire further about these updates, please do not hesitate to reach out to us at investorenquiries@pharmaust.com or visit our website at www.pharmaust.com. We welcome any questions or feedback and are committed to keeping our investors informed.